NEW: No-Cost StreetSmart Live! Events. This type of intellectual capital is usually not made available to the general public. Learn More

Sector Expert: David Lowe

NeuroAssets

Image: David Lowe

Dr. David A. Lowe is president and CEO of NeuroAssets Sarl, a Swiss-based neuroscience-focused consulting firm providing advisory services to pharmaceutical, venture capital and biotechnology companies throughout the world. Lowe previously served as the chief scientific officer of PsychoGenics Inc., and before that as director and chief scientific officer of Memory Pharmaceuticals Corp., a biotechnology company pursuing innovative treatments for Alzheimer's disease and schizophrenia. Prior to Memory Pharmaceuticals, Lowe served as the executive vice president and chief scientific officer at Fidelity Biosciences Group, Fidelity Investments, in Boston, an investment firm focused on the healthcare industry. He also served as president, CEO and director of EnVivo Pharmaceuticals, a Fidelity-funded pharmaceutical company pursuing new treatments for Alzheimer's disease. Lowe has also served as vice president and therapeutic area head, central nervous system (CNS), at Roche Pharmaceuticals, vice president and global therapeutic area head (CNS), at Bayer AG, and head of CNS biology, as well as deputy head of CNS research at Sandoz (now Novartis). He received his PhD in neurobiology from the University of Leeds, UK.



Recent Interviews

From Lab Bench to Bedside: David Lowe Brings Common Sense to Neuroscience Investing (3/26/14)

Billions of dollars have been spent chasing molecular targets in neurological diseases that now appear to be worthless. Effective therapies remain rare. But the market is enormous—and low risk—if a company can get a truly workable solution to patients. Consultant and neuroscientist David Lowe, president and CEO of NeuroAssets, helps biotech firms identify targets and find innovative ways to rapidly move drugs into the clinic. In this interview with The Life Sciences Report, Lowe describes one company with exciting preclinical and clinical-stage assets, and advances two more names worthy of investor attention.

Recent Quotes

"We believe AMBS' MANF molecule is one of the jewels in the field."

The Life Sciences Report Interview with David Lowe (3/26/14)
more >



Due to permission requirements, not all quotes are shown.